AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2035037 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 60
Study 2035037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 6119925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 0.3%
Number of subjects: 40
Study 6119925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 1.5%
Number of subjects: 40
Study 6119925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 2%
Number of subjects: 40
Study 6119925 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 31784433 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Traditional Chinese Medicine (TCM) and Western medicine (Xin Jia Xuan Bai Cheng Qi Decoction)
Number of subjects: 360
Study 31784433 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (Western standard Medicine)
Number of subjects: 360
Study 28967272 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triple disease-modifying anti-rheumatic drug therapy
Number of subjects: 265
Study 28967272 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy with glucocorticoid bridging
Number of subjects: 265
Study 28967272 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 265
Study 26796681 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (AD G)
Number of subjects: 28
Study 26796681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AD P+G)
Number of subjects: 28
Study 24934915 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncultured autologous cell grafting using a six-well plate technique
Number of subjects: 8
Study 21626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 750 mg/m² BID for 14 days of a 21-day cycle
Number of subjects: 32
Study 21626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1,000 mg/m² BID for 14 days of a 21-day cycle
Number of subjects: 32
Study 21626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1,000 mg BID flat dose with continuous dosing of sorafenib 400 mg BID
Number of subjects: 32
Study 21626051 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 19602610 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily icodextrin administration
Number of subjects: 0
Study 19602610 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily icodextrin administration
Number of subjects: 0
Study 17898957 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture combined with Paroxetine
Number of subjects: 42
Study 17898957 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine alone
Number of subjects: 42
Study 15736450 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field (EF) irradiation after four cycles of ABVD regimen
Number of subjects: 210
Study 15736450 — intervention group
Group type: COMPARATOR
Intervention: Involved field (IF) irradiation after four cycles of ABVD regimen
Number of subjects: 210
Study 11790216 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetic agents (various classes)
Number of subjects: 63
Study 11790216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral antidiabetic agents
Number of subjects: 63
Study 11790216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas and metformin
Number of subjects: 63
Study 11790216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 12070396 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water (group A)
Number of subjects: 93
Study 12070396 — intervention group
Group type: COMPARATOR
Intervention: Clinisan (group B)
Number of subjects: 93
Study 9645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 52
Study 9645291 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 52
Study 7935701 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day)
Number of subjects: 206
Study 7935701 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (400 mg per day)
Number of subjects: 206
Study 7935701 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 206
Study 7935701 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 206
Study 3341322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoscillating waterbeds
Number of subjects: 30
Study 3341322 — intervention group
Group type: COMPARATOR
Intervention: Conventional bassinets
Number of subjects: 30
Study 1554112 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 34
Study 1554112 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 34
Study 1554112 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 34
Study 1554112 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 34
Study 894086 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated Mycoplasma pneumoniae vaccine
Number of subjects: 7861
Study 894086 — intervention group
Group type: COMPARATOR
Intervention: Phosphate‐buffered saline with formalin (control)
Number of subjects: 7861
Study 31034314 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Minute Walk Test (2MWT) under dual task conditions overground
Number of subjects: 23
Study 31034314 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Minute Walk Test (2MWT) under dual task conditions on a self-paced treadmill
Number of subjects: 23
Study 31034314 — intervention group
Group type: COMPARATOR
Intervention: Comparison of overground and treadmill velocities
Number of subjects: 23
Study 29615070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 20
Study 26735927 — intervention group
Group type: EXPERIMENTAL
Intervention: Black‐White cardiovascular‐related disparities + neutral health topics
Number of subjects: 86
Study 26735927 — intervention group
Group type: COMPARATOR
Intervention: Neutral health topics only
Number of subjects: 86
Study 24491296 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ovarian suspension for 36-48 hours
Number of subjects: 55
Study 24491296 — intervention group
Group type: COMPARATOR
Intervention: Control (unsuspended ovary)
Number of subjects: 55
Study 22525009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama
Number of subjects: 16
Study 22525009 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 19082851 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD)
Number of subjects: 40
Study 19082851 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 40
Study 17965494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home oxygen therapy (HOT)
Number of subjects: 53
Study 16306060 — intervention group
Group type: EXPERIMENTAL
Intervention: Half the recommended dose of vitamin A
Number of subjects: 4983
Study 16306060 — intervention group
Group type: COMPARATOR
Intervention: Full recommended dose of vitamin A
Number of subjects: 4983
Study 11907388 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (P group, n = 8)
Number of subjects: 64
Study 11907388 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and tramadol (PT group, n = 29)
Number of subjects: 64
Study 11907388 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and nalbuphine (PN group, n = 27)
Number of subjects: 64
Study 10660202 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART (Continuous Hyperfractionated Accelerated Radiotherapy) delivering 54 Gy in 36 fractions on 12 consecutive days
Number of subjects: 918
Study 10660202 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation delivering 66 Gy in 33 fractions over 6‐7 weeks
Number of subjects: 918
Study 7654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole, 160 mg/800 mg twice daily
Number of subjects: 147
Study 7654268 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin, 100 mg four times daily
Number of subjects: 147
Study 7654268 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil, 500 mg twice daily
Number of subjects: 147
Study 7654268 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, 500 mg three times daily
Number of subjects: 147
Study 1969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.167 microgram/kg
Number of subjects: 20
Study 1969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.33 microgram/kg
Number of subjects: 20
Study 1969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.67 microgram/kg
Number of subjects: 20
Study 1969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram/kg
Number of subjects: 20
Study 1969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 20
Study 1969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (optimal dose range)
Number of subjects: 20
Study 435650 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 435650 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 31630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach (COACH) provided by a team including village doctor, aging worker, and psychiatrist for 12 months
Number of subjects: 38
Study 31630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach (COACH)
Number of subjects: 38
Study 31664444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 2500 mg of l-citrulline and 250 mg of metformin 3 times a day for 26 weeks
Number of subjects: 47
Study 31664444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 47
Study 31664444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29102983 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated access to an alcohol reduction website (via brochure from GP)
Number of subjects: 763
Study 29102983 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face brief intervention (BI)
Number of subjects: 763
Study 26475629 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian Heart Lifestyle Intervention (SAHELI) - 6 interactive group classes focused on increasing physical activity, healthful diet, weight, and stress management, plus follow-up telephone support calls.
Number of subjects: 63
Study 26475629 — intervention group
Group type: COMPARATOR
Intervention: Control group received translated print education materials about ASCVD and healthy behaviors.
Number of subjects: 63
Study 24592670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based text messaging intervention
Number of subjects: 5
Study 24592670 — intervention group
Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 5
Study 22320028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ketamine administered as a bolus dose of 0.5 mg/kg in 10 mL of normal saline and a continuous intravenous infusion of 4.0 microg/kg/min
Number of subjects: 34
Study 22320028 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (equal volume to ketamine)
Number of subjects: 34
Study 19772450 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified titration algorithm (6 U per meal starting dose, adjusted in 2-U increments)
Number of subjects: 358
Study 19772450 — intervention group
Group type: COMPARATOR
Intervention: Intensive titration algorithm (doses based on fasting blood glucose, gender, height, and weight, adjusted based on previous 3 days' mean SMBG)
Number of subjects: 358
Study 19772450 — intervention group
Group type: COMPARATOR
Intervention: Intensive titration
Number of subjects: 358
Study 19772450 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified titration
Number of subjects: 358
Study 17313424 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month reducing course of oral prednisolone (9 men)
Number of subjects: 21
Study 17313424 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen (12 men)
Number of subjects: 21
Study 15198881 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (7 mg, oral capsules, one capsule daily for the first 10 days of each month for 3 months)
Number of subjects: 90
Study 15198881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral capsules, one capsule daily for the first 10 days of each month for 3 months)
Number of subjects: 90
Study 15198881 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom
Number of subjects: 90
Study 15198881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12572378 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Wenshen Decoction (JWD)
Number of subjects: 0
Study 12572378 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (LPA)
Number of subjects: 0
Study 9877488 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1.0 mg by inhalation from a pMDI with a Nebuhaler (with charcoal)
Number of subjects: 15
Study 9877488 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1.0 mg by inhalation from a pMDI with a Nebuhaler (without charcoal)
Number of subjects: 15
Study 9877488 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.5 mg given intravenously
Number of subjects: 15
Study 9877488 — intervention group
Group type: EXPERIMENTAL
Intervention: Erroneous administration (canister shaken only before the first actuation)
Number of subjects: 15
Study 7891985 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine, topically twice daily for 1 week
Number of subjects: 21
Study 7891985 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 21
Study 2617284 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine aspartate
Number of subjects: 21
Study 2617284 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 67895 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB I (cyclophosphamide, vincristine, methyl‐CCNU, and bleomycin)
Number of subjects: 106
Study 67895 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB II (cyclophosphamide, vincristine, methyl‐CCNU, and bleomycin)
Number of subjects: 106
Study 67895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, methyl‐CCNU, and bleomycin
Number of subjects: 106
Study 67895 — intervention group
Group type: EXPERIMENTAL
Intervention: Small cell carcinoma group
Number of subjects: 106
Study 67895 — intervention group
Group type: EXPERIMENTAL
Intervention: Other histologic types
Number of subjects: 106
Study 67895 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 106
Study 29966992 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT + ERP
Number of subjects: 58
Study 29966992 — intervention group
Group type: COMPARATOR
Intervention: ERP
Number of subjects: 58
Study 27337542 — intervention group
Group type: EXPERIMENTAL
Intervention: Representative visual exemplification
Number of subjects: 0
Study 27337542 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 27337542 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual exemplars
Number of subjects: 0
Study 25104223 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative computer game intervention
Number of subjects: 32
Study 22798522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 1376
Study 20876408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 20876408 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 17531897 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic measures such as prostaglandins
Number of subjects: 0
Study 17531897 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients and vigilant management of the third stage of labor
Number of subjects: 0
Study 17531897 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterotonic medications
Number of subjects: 0
Study 16301850 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (PAC group): PPI (bid), amoxicillin (1,000 mg, bid), clarithromycin (500 mg, bid)
Number of subjects: 149
Study 16301850 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (PBMT group): PPI (bid), bismuth subcitrate (300 mg, qid), metronidazole (500 mg, tid), tetracycline (500 mg, qid)
Number of subjects: 149
Study 11932285 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (50 g)
Number of subjects: 24
Study 11932285 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo ingestion
Number of subjects: 24
Study 11932285 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (50 g) during mental stress
Number of subjects: 24
Study 9654311 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v./oral therapy with ciprofloxacin plus metronidazole
Number of subjects: 330
Study 9654311 — intervention group
Group type: COMPARATOR
Intervention: i.v. therapy with ciprofloxacin plus metronidazole
Number of subjects: 330
Study 7628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 25 mg plus oestradiol cypionate 5 mg (Cyclofem)
Number of subjects: 21
Study 7628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate 50 mg plus oestradiol valerate 5 mg (Mesigyna)
Number of subjects: 21
Study 7628206 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Cyclofem and Mesigyna)
Number of subjects: 21
Study 2692825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of ketanserin sublingually
Number of subjects: 37
Study 2692825 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ketanserin intravenously
Number of subjects: 37
Study 2692825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine sublingually
Number of subjects: 37
Study 401691 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsydomine 2 mg
Number of subjects: 8
Study 401691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31845903 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Screening and Brief Intervention (eSBI)
Number of subjects: 0
Study 31845903 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 0
Study 28766127 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women with GDM
Number of subjects: 646
Study 28766127 — intervention group
Group type: COMPARATOR
Intervention: Obese women without GDM
Number of subjects: 646
Study 24101160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively open-ended questions (without skillful reflections)
Number of subjects: 465
Study 24101160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively multiple choice questions (with skillful reflections)
Number of subjects: 465
Study 24101160 — intervention group
Group type: EXPERIMENTAL
Intervention: Including both question types (with skillful reflections)
Number of subjects: 465
Study 22624828 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish Adult Reading Test (DART)
Number of subjects: 103
Study 21494994 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 16
Study 19025527 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg i.v. magnesium sulphate in 100 ml of 0.9% normal saline
Number of subjects: 83
Study 19025527 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 83
Study 19025527 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg i.v. magnesium sulphate
Number of subjects: 83
Study 17157115 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/tramadol (PIT) 325 mg/37.5 mg
Number of subjects: 119
Study 17157115 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (T) 50 mg
Number of subjects: 119
Study 12684211 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal fat infusion (triglyceride emulsion, 2.8 kcal/min)
Number of subjects: 16
Study 12684211 — intervention group
Group type: COMPARATOR
Intervention: Duodenal fat infusion with lipase inhibition (120 mg tetrahydrolipstatin)
Number of subjects: 16
Study 11014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 1-160 mg oral single dose
Number of subjects: 0
Study 11014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 10-160 mg intravenous single dose
Number of subjects: 0
Study 11014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 320 mg oral once daily for 7 days
Number of subjects: 0
Study 11014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 and 120 mg oral once daily for 7 days
Number of subjects: 0
Study 11014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 10, 20, 40, 80, 120, and 160 mg oral once daily for 7 days
Number of subjects: 0
Study 11014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40, 80, or 120 mg oral once daily for 28 days
Number of subjects: 0
Study 11014323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 9190129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity general training program (< 50% of heart rate reserve) for 12 weeks
Number of subjects: 22
Study 9190129 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 22
Study 8185741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Lidocaine 1%
Number of subjects: 76
Study 8185741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Mepivacaine 1%
Number of subjects: 76
Study 8185741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Prilocaine 1%
Number of subjects: 76
Study 8185741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Etidocaine 1%
Number of subjects: 76
Study 8185741 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (Control)
Number of subjects: 76
Study 3590805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (2 g of prednisolone-hemisuccinate every 6 hours for 48 hours)
Number of subjects: 14
Study 3590805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14